| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1003872464 |
| P356 | DOI | 10.1186/1476-4598-11-86 |
| P932 | PMC publication ID | 3546838 |
| P698 | PubMed publication ID | 23171475 |
| P5875 | ResearchGate publication ID | 233744852 |
| P2093 | author name string | Rui Li | |
| Ling Gu | |||
| Andrew R Hoffman | |||
| Li-Ping Chen | |||
| Bang-Shun He | |||
| Shu-Kui Wang | |||
| Yu-Qin Pan | |||
| Ji-Fan Hu | |||
| Zhen-Lin Nie | |||
| Ye-Qiong Xu | |||
| Guo-Qi Song | |||
| Tian-Yi Gao | |||
| P2860 | cites work | CTCF: master weaver of the genome | Q24621388 |
| Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 | Q27860674 | ||
| Heterozygosity with respect to Zfp148 causes complete loss of fetal germ cells during mouse embryogenesis | Q28585214 | ||
| Genomic imprinting: implications for human disease | Q33541538 | ||
| Paramyxovirus entry and targeted vectors for cancer therapy | Q33619238 | ||
| Enhanced therapeutic efficacy by simultaneously targeting two genetic defects in tumors | Q33713001 | ||
| Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data | Q33761673 | ||
| a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer | Q33912833 | ||
| An adenovirus mutant that replicates selectively in p53-deficient human tumor cells | Q34399844 | ||
| Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials | Q34452020 | ||
| The APC/C and CBP/p300 cooperate to regulate transcription and cell-cycle progression | Q34471741 | ||
| Adenoviral gene therapy | Q34537888 | ||
| Targeted tumor gene therapy based on loss of IGF2 imprinting | Q34581769 | ||
| Adenoviral vector-mediated gene transfer for human gene therapy | Q34729274 | ||
| Interruption of intrachromosomal looping by CCCTC binding factor decoy proteins abrogates genomic imprinting of human insulin-like growth factor II. | Q34918219 | ||
| Selectively replicating oncolytic adenoviruses as cancer therapeutics | Q34999117 | ||
| Intravascular adenoviral agents in cancer patients: lessons from clinical trials | Q35043094 | ||
| Potentiation of tumor radiotherapy by a radiation-inducible oncolytic and oncoapoptotic adenovirus in cervical cancer xenografts | Q35054432 | ||
| Correction of aberrant imprinting of IGF2 in human tumors by nuclear transfer-induced epigenetic reprogramming | Q35130964 | ||
| Induction of interferon pathways mediates in vivo resistance to oncolytic adenovirus | Q35285768 | ||
| Viral vectors for cancer gene therapy: viral dissemination and tumor targeting | Q36002700 | ||
| CTCF regulates allelic expression of Igf2 by orchestrating a promoter-polycomb repressive complex 2 intrachromosomal loop | Q36959918 | ||
| The current status of adenovirus-based cancer gene therapy | Q37156280 | ||
| Adenoviral E1A function through Myc. | Q37360806 | ||
| Oncolytic virotherapy reaches adolescence | Q37782043 | ||
| Adenovirus as a new agent for multiple myeloma therapies: Opportunities and restrictions | Q37977063 | ||
| Cancer targeting Gene-Viro-Therapy of liver carcinoma by dual-regulated oncolytic adenovirus armed with TRAIL gene | Q39575065 | ||
| CTCF mediates interchromosomal colocalization between Igf2/H19 and Wsb1/Nf1. | Q43651581 | ||
| Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. | Q44183106 | ||
| E1A: tumor suppressor or oncogene? Preclinical and clinical investigations of E1A gene therapy | Q45882584 | ||
| A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis | Q46050836 | ||
| Multipoint imprinting analysis in sporadic colorectal cancers with and without microsatellite instability. | Q52539921 | ||
| Analysis of genomic imprinting of insulin-like growth factor 2 in colorectal cancer. | Q53404629 | ||
| Parental imprinting of the mouse insulin-like growth factor II gene. | Q55052428 | ||
| Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability | Q77534962 | ||
| P921 | main subject | colorectal cancer | Q188874 |
| Adenoviridae | Q193447 | ||
| gene therapy | Q213901 | ||
| oncolytic virus | Q1560099 | ||
| P304 | page(s) | 86 | |
| P577 | publication date | 2012-11-21 | |
| P1433 | published in | Molecular Cancer | Q15724585 |
| P1476 | title | Gene therapy for colorectal cancer by an oncolytic adenovirus that targets loss of the insulin-like growth factor 2 imprinting system | |
| P478 | volume | 11 |
| Q34511282 | Alcohol, one-carbon nutrient intake, and risk of colorectal cancer according to tumor methylation level of IGF2 differentially methylated region. |
| Q42132810 | Amelioration of carbon tetrachloride-induced cirrhosis and portal hypertension in rat using adenoviral gene transfer of Akt. |
| Q34427314 | Distinct allelic expression patterns of imprinted IGF2 in adenocarcinoma and squamous cell carcinoma of the lung |
| Q37588289 | Loss of insulin-like growth factor II imprinting is a hallmark associated with enhanced chemo/radiotherapy resistance in cancer stem cells |
| Q27468694 | Systems Biology-Based Investigation of Cellular Antiviral Drug Targets Identified by Gene-Trap Insertional Mutagenesis |
| Q35095100 | Therapeutic effect of the treatment for colorectal cancer with adenoviral vectors mediated estrogen receptor β gene therapy combined with thermotherapy |
Search more.